Effects of Methylphenidate and Bupropion on DHEA-S and Cortisol Plasma Levels in Attention-deficit Hyperactivity Disorder

Lee, Moon Soo; Yang, Jae Won; Ko, Young Hoon; Han, Changsu; Kim, Seung Hyun; Lee, Min Soo; Joe, Sook Haeng; Jung, In Kwa

doi:10.1007/s10578-007-0081-6

Cited by 38 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study many of the children and adolescents with PAE + ELA reported medication use at study enrollment (primarily stimulant and non-stimulant medications typically prescribed for ADHD, and atypical antipsychotics, as noted), and these children showed significantly lower morning cortisol levels compared to both children with PAE + ELA who were not taking medications and controls. Findings from studies examining the effects of these types of medications on cortisol levels are mixed, showing either elevated basal cortisol levels or no effects (Isaksson, Hogmark, Nilsson, & Lindblad, 2013; Lee et al, 2008; Wang, Huang, Hsiao, & Chen, 2012). At least one study has shown an opposite pattern of findings in children with combined-type ADHD, with more typical morning cortisol levels in children taking stimulant medications, and depressed morning levels in those untreated (Kariyawasam, Zaw, & Handley, 2002).…”

Section: Discussionmentioning

confidence: 99%

Dysregulation of the cortisol diurnal rhythm following prenatal alcohol exposure and early life adversity

McLachlan

Rasmussen

Oberlander

et al. 2016

Alcohol

View full text Add to dashboard Cite

The hypothalamic-pituitary-adrenal (HPA) axis is impacted by a multitude of pre- and postnatal factors. Developmental programming of HPA axis function by prenatal alcohol exposure (PAE) has been demonstrated in animal models and in human infants, but remains understudied in older children and adolescents. Moreover, early life adversity (ELA), which occurs at higher rates in children with PAE than in non-exposed children, may also play a role in programming the HPA or stress response system. In a cohort of children and adolescents with PAE and ELA (PAE + ELA), we evaluated HPA function through assessment of diurnal cortisol activity compared to that in typically developing controls, as well as the associations among specific ELAs, adverse outcomes, protective factors, and diurnal cortisol. Morning and evening saliva samples were taken under basal conditions from 42 children and adolescents (5–18 years) with PAE + ELA and 43 typically developing controls. High rates of ELA were shown among children with PAE, and significantly higher evening cortisol levels and a flatter diurnal slope were observed in children with PAE + ELA, compared to controls. Medication use in the PAE + ELA group was associated with lower morning cortisol levels, which were comparable to controls. Complex associations were found among diurnal cortisol patterns in the PAE + ELA group and a number of ELAs and later adverse outcomes, whereas protective factors were associated with more typical diurnal rhythms. These results complement findings from research on human infants and animal models showing dysregulated HPA function following PAE, lending weight to the suggestion that PAE and ELA may interact to sensitize the developing HPA axis. The presence of protective factors may buffer altered cortisol regulation, underscoring the importance of early assessment and interventions for children with FASD, and in particular, for the many children with FASD who also have ELA.

show abstract

Section: Discussionmentioning

confidence: 99%

Dysregulation of the cortisol diurnal rhythm following prenatal alcohol exposure and early life adversity

McLachlan

Rasmussen

Oberlander

et al. 2016

Alcohol

View full text Add to dashboard Cite

show abstract

“…We did not collect any information on medication use prior to sample collection days. Several medications used to treat common childhood behavior problems influence sex hormone levels (Hibel et al 2007; Lee et al 2008), although it is unknown to what extent these effects persists beyond medication use. Similarly, we did not obtain information on menstrual cycles in females, although roughly half the sample reported having started menstruating.…”

Section: Discussionmentioning

confidence: 99%

Genetic and Environmental Contributions to Covariation Between DHEA and Testosterone in Adolescent Twins

et al. 2015

View full text Add to dashboard Cite

Although several studies have shown that pubertal tempo and timing are shaped by genetic and environmental factors, few studies consider to what extent endocrine triggers of puberty are shaped by genetic and environmental factors. Doing so moves the field from examining correlated developmentally-sensitive biomarkers toward understanding what drives those associations. Two puberty related hormones, dehydroepiandrosterone and testosterone, were assayed from salivary samples in 118 MZ (62 % female), 111 same sex DZ (46 % female) and 103 opposite-sex DZ twin pairs, aged 12–16 years (M = 13.1, SD = 1.3). Pubertal status was assessed with a composite of mother- and self-reports. We used biometric models to estimate the genetic and environmental influences on the variance and covariance in testosterone and DHEA, with and without controlling for their association with puberty, and to test for sex differences. In males, the variance in testosterone and pubertal status was due to shared and non-shared environmental factors; variation in DHEA was due to genetic and non-shared environmental factors. In females, variance in testosterone was due to genetic and non-shared environmental factors; genetic, shared, and non-shared environmental factors contributed equally to variation in DHEA. In males, the testosterone-DHEA covariance was primarily due to shared environmental factors that overlapped with puberty as well as shared and non-shared environmental covariation specific to testosterone and DHEA. In females, the testosterone-DHEA covariance was due to genetic factors overlapping with pubertal status, and shared and non-shared environmental covariation specific to testosterone and DHEA.

show abstract

“…MPH treatment may lead to several adverse effects, including decreased appetite, sleep disturbance, headache, anxiety, irritability, and rarely occurring cardiovascular adverse events (Cortese et al, 2013; Martinez-Raga et al, 2013). Moreover, researchers have noticed that MPH treatment potentially affects the endocrine system of patients (Maayan et al, 2003; Lee et al, 2008; Wang et al, 2011, 2014). More recently, controversies have emerged regarding whether MPH interferes with the gonadal function of children, particularly testosterone levels.…”

Section: Introductionmentioning

confidence: 99%

Does Methylphenidate Reduce Testosterone Levels in Humans? A Prospective Study in Children with Attention-Deficit/Hyperactivity Disorder

Wang

Chou

et al. 2016

IJNPPY

View full text Add to dashboard Cite

Background:Animal studies and case reports have suggested that methylphenidate exerts adverse effects on gonadal hormones. This study aimed to determine whether methylphenidate alters testosterone levels in children with attention-deficit/hyperactivity disorder through comparison of those with or without methylphenidate treatment.Methods:This 4-week, nonrandomized, prospective study conducted in Taiwan included 203 attention-deficit/hyperactivity disorder patients with a mean age of 8.7 years (boys: 75.8%). After the initial recruitment, 137 received daily methylphenidate treatment (medicated group) and 66 were assessed through naturalistic observation (nonmedicated group). The saliva samples of attention-deficit/hyperactivity disorder patients were used to quantify testosterone levels at baseline and the endpoint by using the chemiluminescence immunoassay. At the 4th week, 86 patients in the medicated group and 46 patients in the nonmedicated group were eligible for statistical analyses.Results:During the study period, salivary testosterone levels did not significantly change in the medicated group (P=.389) or in the nonmedicated group (P=.488). After correction for the potential confounding effects of age and sex, salivary testosterone levels still remained unchanged in the medicated and nonmedicated groups during the 4-week follow-up. In the medicated group, changes in salivary testosterone levels over 4 weeks were not significantly correlated with the methylphenidate daily dose (mean daily dose: 18.1 mg).Conclusions:Findings suggest that short-term treatment with methylphenidate at usual doses does not significantly alter salivary testosterone levels in attention-deficit/hyperactivity disorder patients. Future studies should clarify whether long-term methylphenidate treatment disrupts testosterone production as well as the function of the reproductive system.

show abstract

Effects of Methylphenidate and Bupropion on DHEA-S and Cortisol Plasma Levels in Attention-deficit Hyperactivity Disorder

Cited by 38 publications

References 21 publications

Dysregulation of the cortisol diurnal rhythm following prenatal alcohol exposure and early life adversity

Dysregulation of the cortisol diurnal rhythm following prenatal alcohol exposure and early life adversity

Genetic and Environmental Contributions to Covariation Between DHEA and Testosterone in Adolescent Twins

Does Methylphenidate Reduce Testosterone Levels in Humans? A Prospective Study in Children with Attention-Deficit/Hyperactivity Disorder

Contact Info

Product

Resources

About